Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

By Banu Eugeniu  

Drugs & Aging, Vol. 24, Iss. 10, 2007-01 ,pp. : 865-879

Adis International

Access to resources Recommend Favorite

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

By Richards Donald   Kuefler Paul   Becerra Carlos   Wilfong Lalan   Gersh Robert   Boehm Kristi   Zhan Feng   Asmar Lina   Myrand Scott   Hozak Rebecca   Zhao Luping   Gill John   Mullaney Brian   Obasaju Coleman   Nicol Steven  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 144-153

Springer Publishing Company

Access to resources Recommend Favorite

PEFG superior to gemcitabine for advanced pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen

By Serdjebi Cindy   Seitz Jean-François   Ciccolini Joseph   Duluc Muriel   Norguet Emmanuelle   Fina Frédéric   Lacarelle Bruno   Ouafik L'Houcine   Dahan Laetitia  

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 1047-1051

Future Medicine

Access to resources Recommend Favorite

Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study

By Karasek Petr   Skacel Tomas   Kocakova Ilona   Bednarik Otakar   Petruzelka Lubos   Melichar Bohuslav   Bustova Ivana   Spurny Vladimir   Trason Tomas  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 581-586

Informa Healthcare

Access to resources Recommend Favorite